ANRO Earnings & Financial Statements
Alto Neuroscience, Inc.
$24.03
+$0.51(+2.17%)
39
Overall
60
Value
27
Tech
31
Quality
Market Cap
$922.97M
Volume
409.76K
52W Range
$5.23 - $37.48
Target Price
$37.67
ANRO earnings and financial statements: Alto Neuroscience, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ANRO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$66.36M | -$68.61M | -$37.81M | -$29.19M |
| EBITDA | -$59.33M | -$59.22M | -$34.42M | - |
| Net income | -$63.24M | -$61.43M | -$36.30M | -$26.97M |
| EPS (diluted) | $-2.19 | $-2.50 | $-9.73 | $-8.04 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $184.69M | $177.54M | $86.63M | $50.85M |
| Total liabilities | $33.55M | $26.08M | $16.82M | $17.02M |
| Shareholders’ equity | $151.14M | $151.46M | $69.81M | $33.83M |
| Cash and equivalents | $176.50M | $168.20M | $82.55M | $48.34M |
| Long-term debt | $22.22M | $16.07M | $9.86M | $9.59M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$51.77M | -$47.42M | -$33.45M | -$20.39M |
| Capital expenditure | -$24.0K | -$2.08M | - | - |
| Free cash flow | -$51.79M | -$49.50M | -$33.92M | -$21.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANRO | $24.03 | +2.2% | 409.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |